Your shopping cart is currently empty

c-MYC/BCL2 ligand 1 iodide is a dual-target ligand that specifically interacts with the G-quadruplex (G4) regions of the c-MYC and Bcl-2 promoters, exhibiting Kd values of 0.90 μM for c-MYCG4 and 0.56 μM for Bcl-2G4. It works by binding to these G4-forming sequences to inhibit transcription of the c-MYC and Bcl-2 genes, leading to reduced protein expression. This compound effectively suppresses MCF-7 cell proliferation and migration, induces G1 phase cell cycle arrest, and triggers apoptosis. Additionally, it significantly hampers tumor growth in the 4T1 homogenous model with negligible toxicity. c-MYC/BCL2 ligand 1 iodide is applicable in breast cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | c-MYC/BCL2 ligand 1 iodide is a dual-target ligand that specifically interacts with the G-quadruplex (G4) regions of the c-MYC and Bcl-2 promoters, exhibiting Kd values of 0.90 μM for c-MYCG4 and 0.56 μM for Bcl-2G4. It works by binding to these G4-forming sequences to inhibit transcription of the c-MYC and Bcl-2 genes, leading to reduced protein expression. This compound effectively suppresses MCF-7 cell proliferation and migration, induces G1 phase cell cycle arrest, and triggers apoptosis. Additionally, it significantly hampers tumor growth in the 4T1 homogenous model with negligible toxicity. c-MYC/BCL2 ligand 1 iodide is applicable in breast cancer research. |
| Targets&IC50 | Bcl-2:0.56 μM (Kd) |
| In vitro | c-MYC/BCL2 ligand 1 iodide (Compound Z4) demonstrates an IC50 of 4.14 μM against 4T1 cells and 5.47 μM against MCF-7 cells. Treatment with c-MYC/BCL2 ligand 1 iodide (2.5-10 μM, 48 h) significantly reduces the expression levels of c-MYC and Bcl-2, inducing apoptosis in MCF-7 cells via a mitochondrial-dependent pathway. Additionally, c-MYC/BCL2 ligand 1 iodide (2.5-10 μM, 24-48 h) hinders cell migration in a dose-dependent manner and inhibits cell proliferation in MCF-7 cells by arresting the cell cycle at the G1 phase. |
| In vivo | c-MYC/BCL2 ligand 1 iodide (Compound Z4) (12 mg/kg; intraperitoneal injection; administered every other day for 21 days) demonstrated significant antitumor efficacy and good safety in a 4T1 breast cancer syngeneic mouse model (female BALB/c; 4-5 weeks old). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.